Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.34 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 5/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135849 | 0.94 | MDM2 (0.36) | PTGER4PLA2G4APIN1VCPKDM4E | |
| SCHEMBL5137318 | 0.88 | PIN1 (0.36) | PTGER4PLA2G4APIN1KDM4EALDH1A1 | |
| SCHEMBL5136239 | 0.82 | L3MBTL1 (0.34) | ALDH1A1 | |
| SCHEMBL652150 | 0.82 | CRHR1 (0.38) | — | |
| SCHEMBL5136020 | 0.80 | PTGER4 (0.41) | PTGER4PLA2G4APIN1KDM4EALDH1A1 | |
| SCHEMBL650362 | 0.78 | TLR7 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL5138076 | 0.77 | AGTR1 (0.36) | PLA2G4APIN1 | |
| SCHEMBL651143 | 0.77 | CRHR1 (0.37) | — | |
| SCHEMBL651001 | 0.76 | CRHR1 (0.38) | PIN1 | |
| SCHEMBL5137377 | 0.75 | PTGS2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |